NASDAQ:SLDB Solid Biosciences Q3 2024 Earnings Report $9.80 +0.08 (+0.82%) As of 01:47 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Solid Biosciences EPS ResultsActual EPS-$0.79Consensus EPS -$0.67Beat/MissMissed by -$0.12One Year Ago EPSN/ASolid Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASolid Biosciences Announcement DetailsQuarterQ3 2024Date11/6/2024TimeAfter Market ClosesConference Call DateWednesday, November 6, 2024Conference Call Time1:30AM ETUpcoming EarningsSolid Biosciences' Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Solid Biosciences Earnings HeadlinesAnalysts Conflicted on These Healthcare Names: Nuvalent (NUVL) and Solid Biosciences (SLDB)July 7, 2026 | theglobeandmail.comSolid Biosciences (NASDAQ:SLDB) Upgraded to "Sell" at Wall Street ZenJuly 4, 2026 | americanbankingnews.comWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% over 3-4 years, with some subscribers reporting gains of $141,000, $272,000, and even over $1 million. Now Karim sees a similar setup in what he calls the Energy Cube - a misunderstood technology backed by Bill Gates, Jeff Bezos, Google, and Microsoft. A major government milestone is expected this August that could force Wall Street to finally pay attention. Watch Karim's full presentation and learn why this overlooked opportunity may not stay overlooked for long.July 14 at 1:00 AM | Monument Traders Alliance (Ad)Solid Biosciences: The Bull Case Is No Longer Just DuchenneJuly 2, 2026 | seekingalpha.comDoes Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?July 1, 2026 | finance.yahoo.comSolid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comSee More Solid Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Solid Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Solid Biosciences and other key companies, straight to your email. Email Address About Solid BiosciencesSolid Biosciences (NASDAQ:SLDB) is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein. Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector. In addition to SGT‐001, the company is advancing next-generation programs including SGT-003, a CRISPR/Cas9‐based gene editing approach aimed at correcting specific dystrophin gene mutations, and proprietary assays for sensitive detection of dystrophin expression in muscle tissue. Founded in 2015 and headquartered in Cambridge, Massachusetts, Solid Biosciences leverages partnerships with academic institutions and patient advocacy groups to support clinical development and expand its understanding of DMD biology. Its clinical studies have been conducted at sites across the United States and Europe, reflecting the global nature of DMD research and the need for broad patient enrollment in rare-disease trials. Under the leadership of Chief Executive Officer Ilan Ganot, Solid Biosciences maintains a network of research and manufacturing collaborations to enhance vector production and assay development. The company’s mission remains to deliver transformative therapies to DMD patients by advancing innovative genetic medicines and building the infrastructure required for efficient clinical translation.View Solid Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Prepare for the Next Wave of Factory Automation With These 3 Standout NamesAnalysts See Major Upside for These 5 StocksMarketBeat Week in Review – 07/06 - 07/10Delta Air Lines Lives Up to Its Claims: Shares Can Keep ClimbingWhy WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software Costs Upcoming Earnings Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026)Bank of New York Mellon (7/15/2026)Morgan Stanley (7/15/2026)Progressive (7/15/2026)The PNC Financial Services Group (7/15/2026)Elevance Health (7/15/2026)Johnson & Johnson (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
